Surrozen discontinues SZN-1326; SZN-043 Phase 1a complete, data due Q1 2024

Surrozen, Inc./DE

SZN-043 Phase 1a enrollment in chronic liver disease and healthy volunteers complete; safety/pharmacodynamic data expected Q1 2024.
Phase 1b for alcohol-associated hepatitis to initiate soon; proof-of-concept data possible in H2 2024.
SZN-1326 development in IBD discontinued due to asymptomatic grade 3 ALT/AST elevations at high doses and strategic factors.
No serious adverse events in SZN-1326 trial; transaminase elevations resolved spontaneously in all subjects.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.